India Pharma Outlook Team | Monday, 18 May 2026
Glenmark Pharmaceuticals announced the launch of its affordable Vancomycin Hydrochloride for Injection USP in the U.S. market in two strengths, 500 mg/vial and 1 g/vial.
Marc Kikuchi, President and Business Head of the North American wing of Glenmark Pharmaceuticals, commented, “The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark’s continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients.”
The United States has been facing a shortage of affordable vancomycin. Vancomycin is a powerful antibiotic used for treating serious bacterial infections, including Methicillin-Resistant Staphylococcus aureus (MRSA).
The vancomycin market has been dominated by a few injectable drug makers, making it expensive for health care providers. Glenmark Pharmaceuticals is now closing that gap, launching its own vancomycin hydrochloride for injection in 500 mg and 1 g vials.
As per the IQVIA sales data for the 12 months ending March 2026, the vancomycin hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of approximately USD 37.9 million.
Also Read: India's Path to Billion-Dollar Drugs: Building a Strong Ecosystem
This move is not simply a product launch. It is a calculated entry by an Indian-origin global pharmaceutical company to carve out a meaningful share in a high-value US injectable segment by offering a bioequivalent, therapeutically equivalent alternative to the reference listed drug manufactured by Fresenius Kabi USA.
For American Hospitals, which purchase vancomycin in bulk for Intensive Care Units and surgical wards, this is expected to give relief from the high prices. Glenmark’s entry into the vancomycin market reflects the strategy of Indian Pharmaceutical companies targeting the US injectable market.
A generic injectable that competes directly with an established brand on price and quality will fit the requirements of hospital procurement and pharmacy teams.
Vancomycin has been a cornerstone of hospital infection treatment for decades. It remains one of the few effective options against Gram-positive bacterial infections that have developed resistance to other antibiotics. This makes the reliable and affordable supply of vancomycin a genuine public health consideration.
Glenmark's entry into this market adds a layer of supply resilience. The USD 37.9 billion annual market figures reflect the steady demand for the product.
Glenmark Pharmaceuticals is a research-oriented, multinational pharmaceutical company headquartered in Mumbai, India. It specializes in the development, manufacture, and distribution of branded drugs, affordable generics, and over-the-counter (OTC) medicines.
In March 2026, Glenmark launched a new diabetes drug Glipiq, in India. Glipiq was launched in pen and vial forms, giving flexibility to both doctors and patients. This move was noted for its pricing strategy. The company introduced Glipiq as an affordable diabetes drug, offering a significantly lower cost compared to similar therapies available globally.
.jpg)
.jpg)
